Stacey M. Lee, DMSc, PA-C

Gilead Sciences, Inc.

Poster(s):

• A0467 - Bulevirtide Monotherapy at Low and High Dose in Patients With Chronic Hepatitis Delta: 24-Week Interim Data of the Phase 3 MYR301 Study
  Sunday, October 23, 2022

  5:00 PM – 7:00 PM ET